Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis

Cardoso, Abel Silveira; Moucari, Rami; Figueiredo-Mendes, C.; Ripault, Marie–Pierre; Giuily, Nathalie; Castelnau, Corinne; Boyer, Nathalie; Asselah, Tarik; Martinot–Peignoux, Michelle; Maylin, Sarah; Carvalho-Filho, Roberto José de; Valla, Dominique; Bédossa, Pierre; Marcellin, Patrick

doi:10.1016/j.jhep.2009.12.028

Cited by 305 publications

(240 citation statements)

References 39 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…This would not have been the case if we had considered HCC or decompensation, which may be subject to interval censoring and, in addition, to a bias of diagnosis. Moreover, a previous analysis of the same cohort found that SVR patients had significantly lower chances of HCC and liver complications than non-SVR patients (22). Consistent with this finding, results from the HALT-C trial showed a lower incidence of HCC in patients randomized to long-term, low-dose pegylated interferon; however, the difference emerged only after 5 to 7 years of follow-up (23).…”

Section: Discussionsupporting

confidence: 64%

Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

Kutala

Guedj

Asselah

et al. 2015

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The beneficial effect of achieving a sustained virological response (SVR) after antiviral treatment against hepatitis C virus is well established. However, it remains unclear whether unsuccessful treatment (non-SVR) also improves patient survival, especially in patients with advanced liver fibrosis. We retrospectively evaluated the incidence of death or liver transplantation in the 427 naive patients with a Child-Pugh score of A and advanced fibrosis newly admitted to the Hospital Beaujon between 2000 and 2010. Patients were followed for a median time of 5.5 years. The baseline characteristics of untreated (n ‫؍‬ 102) and treated (n ‫؍‬ 325) patients were largely similar, and there was no evidence of a bias of indication. Treated patients received a combination of interferon and ribavirin and had an SVR rate of 32%. The incidence of death or liver transplantation per 100 person-years was 1.00, 3.20, and 5.44 in SVR, non-SVR, and untreated patients, respectively. After adjusting for baseline characteristics, the risk of death or liver transplantation was significantly lower in SVR than in non-SVR patients and in non-SVR than in untreated patients (hazard ratios, 0.35 and 0.51, respectively; P ‫؍‬ 0.019 and 0.038, respectively). The effect of treatment in non-SVR patients was higher in patients who had a virological or a biochemical response than in those who did not have a virological or a biochemical response. The risk of death or liver transplantation was significantly lower in treated than in untreated patients. Moreover, there was a gradient of mortality between patients with SVRs, virological or biochemical responders, and untreated patients, suggesting that treatment, even in the absence of viral eradication, has a beneficial effect on survival.

show abstract

Section: Discussionsupporting

confidence: 64%

Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

Kutala

Guedj

Asselah

et al. 2015

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although several clinical studies have demonstrated that eradication of HCV with IFN-based regimens results in the suppression of liver carcinogenesis [49][50][51], HCC can still develop after viral eradication. Indeed, the 5-year HCC incidence after SVR by IFN-based antiviral therapy for HCV-related chronic liver disease is 2.3-8.8 % [52].…”

Section: Introductionmentioning

confidence: 99%

Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis

et al. 2016

View full text Add to dashboard Cite

Hepatitis virus infection is a leading cause of chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). Although anti-viral therapies against hepatitis B virus (HBV) and hepatitis C virus (HCV) have dramatically progressed during the past decade, the estimated number of people chronically infected with HBV and/or HCV is *370 million, and hepatitis virus-associated hepatocarcinogenesis is a serious health concern worldwide. Understanding the mechanism of virus-associated carcinogenesis is crucial toward both treatment and prevention, and the recently developed whole genome/exome sequencing analysis using next-generation sequencing technologies has contributed to unveiling the landscape of genetic and epigenetic aberrations in not only tumor tissues but also the background liver tissues underlying chronic liver damage caused by hepatitis virus infection. Several major mechanisms underlie the genetic and epigenetic aberrations in the hepatitis virus-infected liver, such as the generation of reactive oxidative stress, ectopic expression of DNA mutator enzymes, and dysfunction of the DNA repair system. In addition, direct oncogenic effects of hepatitis virus, represented by the integration of HBV-DNA, are observed in infected hepatocytes. Elucidating the whole picture of genetic and epigenetic alterations, as well as the mechanisms of tumorigenesis, will facilitate the development of efficient treatment and prevention strategies for hepatitis virus-associated HCC.

show abstract

“…Elimination of HCV resulted in a decrease of 5-year-mortality by 62-84%; the risk for development of HCC was lowered by 68-79%; the risk for liver transplantation was lowered by 90% [38]. A post hoc analysis of the HALT-C trial confirmed two prior large retrospective follow-up studies from Italy and France in which the incidence of HCC among patients with SVR was significantly lower compared to those without SVR [39][40][41]. Morgan et al [42] described a similar HCC risk reduction with SVR among patients with all stages of fibrosis (HR 0.24) with a separate analysis, although predominantly including studies from Asia where the risk of HCC is substantially higher.…”

Section: Hepatocellular Carcinoma and Daas: A Controversial Storymentioning

confidence: 75%

Current and future challenges in HCV: insights from an Italian experts panel

et al. 2017

View full text Add to dashboard Cite

show abstract

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis

Cited by 305 publications

References 39 publications

Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis

Current and future challenges in HCV: insights from an Italian experts panel

Contact Info

Product

Resources

About